{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:24:27Z","timestamp":1786937067959,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,9,5]]},"DOI":"10.1038\/s41416-026-03457-3","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:34:52Z","timestamp":1780410892000},"page":"808-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of VEGFA\/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer"],"prefix":"10.1038","volume":"135","author":[{"given":"Ryoko Inaba","family":"Higashiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4896-5824","authenticated-orcid":false,"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-7400","authenticated-orcid":false,"given":"Kouya","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Torasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9401-6286","authenticated-orcid":false,"given":"Masayuki","family":"Shirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-801X","authenticated-orcid":false,"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Tuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2632-1334","authenticated-orcid":false,"given":"Ryuji","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1788-559X","authenticated-orcid":false,"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5371-706X","authenticated-orcid":false,"given":"Takashi","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"3457_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"3457_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"3457_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","volume":"10","author":"CS Abhinand","year":"2016","unstructured":"Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran PR. VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal. 2016;10:347\u201354.","journal-title":"J Cell Commun Signal"},{"key":"3457_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","volume":"16","author":"X Le","year":"2021","unstructured":"Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, et al. Dual EGFR\u2013VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol. 2021;16:205\u201315.","journal-title":"J Thorac Oncol"},{"key":"3457_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","volume":"10","author":"Y Kawashima","year":"2022","unstructured":"Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022;10:72\u201382.","journal-title":"Lancet Respir Med"},{"key":"3457_CR6","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:1655\u201369.","journal-title":"Lancet Oncol"},{"key":"3457_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jtho.2022.05.008","volume":"17","author":"MC Piccirillo","year":"2022","unstructured":"Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, et al. Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancer: the BEVERLY multicenter randomized phase 3 trial. J Thorac Oncol. 2022;17:1086\u201397.","journal-title":"J Thorac Oncol"},{"key":"3457_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","volume":"39","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell. 2021;39:1279\u201391.e3.","journal-title":"Cancer Cell"},{"key":"3457_CR9","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1002\/cncr.26540","volume":"118","author":"SE Abdullah","year":"2012","unstructured":"Abdullah SE, Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer. 2012;118:3455\u201367.","journal-title":"Cancer"},{"key":"3457_CR10","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1078-0432.CCR-13-0051","volume":"19","author":"JH McCarty","year":"2013","unstructured":"McCarty JH. Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET? Clin Cancer Res. 2013;19:1631\u20133.","journal-title":"Clin Cancer Res"},{"key":"3457_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li H, Durbin R. Fast and accurate long-read alignment with Burrows\u2013Wheeler transform. Bioinformatics. 2010;26:589\u201395.","journal-title":"Bioinformatics"},{"key":"3457_CR12","doi-asserted-by":"publisher","DOI":"10.5808\/GI.2020.18.1.e10","volume":"18","author":"KR Franke","year":"2020","unstructured":"Franke KR, Crowgey EL. Accelerating next-generation sequencing data analysis: an evaluation of optimized best practices for Genome Analysis Toolkit algorithms. Genom Inform. 2020;18:e10.","journal-title":"Genom Inform"},{"key":"3457_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"3457_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"3457_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinforma. 2011;12:323.","journal-title":"BMC Bioinforma"},{"key":"3457_CR16","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1126\/science.abl9283","volume":"376","author":"A Degasperi","year":"2022","unstructured":"Degasperi A, Zou X, Amarante TD, Martinez-Martinez A, Koh GCC, Dias JML, et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science. 2022;376:6591.","journal-title":"Science"},{"key":"3457_CR17","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1158\/0008-5472.CAN-05-3090","volume":"66","author":"N Pore","year":"2006","unstructured":"Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor-1-independent and -dependent mechanisms. Cancer Res. 2006;66:3197\u2013204.","journal-title":"Cancer Res"},{"key":"3457_CR18","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","volume":"15","author":"GN Naumov","year":"2009","unstructured":"Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15:3484\u201394.","journal-title":"Clin Cancer Res"},{"key":"3457_CR19","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","volume":"23","author":"M Canale","year":"2017","unstructured":"Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res. 2017;23:2195\u2013202.","journal-title":"Clin Cancer Res"},{"key":"3457_CR20","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-21-0273","volume":"27","author":"K Nakagawa","year":"2021","unstructured":"Nakagawa K, Nadal E, Garon EB, Nishio M, Seto T, Yamamoto N, et al. RELAY subgroup analyses by EGFR exon 19 deletion and exon 21 L858R mutations for ramucirumab plus erlotinib in metastatic non-small-cell lung cancer. Clin Cancer Res. 2021;27:5258\u201371.","journal-title":"Clin Cancer Res"},{"key":"3457_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/annonc\/mdv598","volume":"27","author":"K Koehler","year":"2016","unstructured":"Koehler K, Liebner D, Chen JL. TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol. 2016;27:539\u201343.","journal-title":"Ann Oncol"},{"key":"3457_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high-grade serous carcinoma of the ovary. J Pathol. 2010;221:49\u201356.","journal-title":"J Pathol"},{"key":"3457_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/humu.22552","volume":"35","author":"B Leroy","year":"2014","unstructured":"Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35:672\u201388.","journal-title":"Hum Mutat"},{"key":"3457_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/15384047.2019.1665956","volume":"21","author":"AM Li","year":"2020","unstructured":"Li AM, Boichard A, Kurzrock R. Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. Cancer Biol Ther. 2020;21:95\u2013100.","journal-title":"Cancer Biol Ther"},{"key":"3457_CR25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","volume":"17","author":"H Kenmotsu","year":"2022","unstructured":"Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, et al. Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous non-small-cell lung cancer harboring EGFR mutations (WJOG9717L). J Thorac Oncol. 2022;17:1098\u2013108.","journal-title":"J Thorac Oncol"},{"key":"3457_CR26","first-page":"JCO2400533","volume":"42","author":"X Le","year":"2024","unstructured":"Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, et al. A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor\u2013naive EGFR-mutant metastatic non-small-cell lung cancer (RAMOSE trial). J Clin Oncol. 2024;42:JCO2400533.","journal-title":"J Clin Oncol"},{"key":"3457_CR27","doi-asserted-by":"publisher","first-page":"S1313","DOI":"10.1016\/j.annonc.2023.10.071","volume":"34","author":"Y Nakahara","year":"2023","unstructured":"Nakahara Y, Kato T, Isomura R, Misumi T, Tamiya M, Yoh K, et al. OSIRAM-1: a multicenter, open-label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small-cell lung cancer (TORG1833). Ann Oncol. 2023;34:S1313.","journal-title":"Ann Oncol"},{"key":"3457_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"H Akamatsu","year":"2021","unstructured":"Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, et al. Efficacy of osimertinib plus bevacizumab vs. osimertinib in patients with EGFR T790M-mutated non-small-cell lung cancer previously treated with EGFR tyrosine kinase inhibitors: West Japan Oncology Group 8715L phase 2 randomized clinical trial. JAMA Oncol. 2021;7:386\u201394.","journal-title":"JAMA Oncol"},{"key":"3457_CR29","first-page":"633","volume":"14","author":"J Bao","year":"2022","unstructured":"Bao J, Wu Z, Zhang C, Zhang M, Wang Y, Li H, et al. Efficacy and mechanism of osimertinib combined with bevacizumab in the treatment of postoperative EGFR-positive stage II\u2013IIIA lung adenocarcinoma. Am J Transl Res. 2022;14:633\u201342.","journal-title":"Am J Transl Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03457-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:44:00Z","timestamp":1786934640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03457-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,5]]}},"alternative-id":["3457"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03457-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RIH declares no competing interests. TY has received grants or contracts from Novartis, Amgen, MSD, Astellas, AstraZeneca, Daiichi Sankyo, Boehringer Ingelheim, and Bristol Myers Squibb, and honoraria for lectures, presentations or speakers from AstraZeneca, MSD, Chugai, Daiichi Sankyo, and Pfizer, all outside the submitted work. KS declares no competing interests. JM declares no competing interests. MT declares no competing interests. MS has received personal fees from MSD, Asahi Kasei Pharma Corporation, AstraZeneca, Chugai, Ono, Bristol Myers Squibb, Eli Lilly, and Daiichi Sankyo, all outside the submitted work. KM declares no competing interests. YS has received grants or contracts from Ono Pharmaceutical, Janssen Pharma, Taiho Pharmaceutical, Bayer, AstraZeneca, and Daiichi Sankyo, all outside the submitted work. YM has received consulting fees from Intuitive Surgical and payment or honoraria from Olympus, AstraZeneca, Novartis, Cook Medical, AMCO, Thermo Fisher Scientific, Erbe Elektromedizin GmbH, Fujifilm, Chugai, Eli Lilly, Merck, Takeda, and Ethicon, all outside the submitted work. Yusuke Okuma has received honoraria from AstraZeneca, Chugai, and Eli Lilly, and grants or contracts from AstraZeneca and MSD, all outside the submitted work. Yukihiro Yoshida has received grants or contracts from AstraZeneca, Chugai, and TAKAHATA PRECISION, and payment or honoraria from Medtronic, all outside the submitted work. YG has received grants or contracts from MSD, Novartis, Daiichi Sankyo, Chugai, IQVIA, EPS, and AstraZeneca, and honoraria for lectures, presentations or speakers from Pfizer, Eli Lilly, Chugai, Daiichi Sankyo, and AstraZeneca, all outside the submitted work. HH has received grants or contracts from MSD, AbbVie, Daiichi Sankyo, Janssen Pharma, Amgen, Bristol Myers Squibb, IQVIA, Ono, Takeda, AstraZeneca, Chugai, and Novartis, and honoraria for lectures, presentations or speakers from AstraZeneca, Amgen, and Chugai, all outside the submitted work. TT has received grants or contracts from the JSPS KAKENHI Grant for Medical Research, payment or honoraria from the Nippon Medical School Foundation Degree Examination Review Committee and has served on the Hamamatsu University School of Medicine Safety Monitoring Board, all outside the submitted work. RH has received grants or contracts from the Cabinet Office, Government of Japan, all outside the submitted work. NY has received research grants as principal investigator (institution) from Astellas, Chugai, Eisai, Taiho, Bristol Myers Squibb, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, Ono, Janssen Pharma, MSD, Merck, GlaxoSmithKline, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, Toray, Kaken, AstraZeneca, InventisBio, Rakuten Medical, Amgen, Bicycle Therapeutics, and Zymeworks; has served in an advisory role (personal) for Eisai, Boehringer Ingelheim, CMIC, Chugai, Merck, Healios, Mitsubishi Tanabe, Rakuten Medical, IQVIA, Noile-Immune Biotech, and Janssen Pharma; and has honoraria for speakers from Chugai, Daiichi Sankyo, and Eisai, all outside the submitted work. SW declares no competing interests. Yasushi Yatabe has received grants or contracts from Merck Biopharma Co., Ltd., Chugai, Konica Minolta REALM, Inc., Optieum Biotechnologies, and Eisai; consulting fees from AstraZeneca, MSD, AbbVie, Novartis, and Amgen; honoraria for advisory board participation from Daiichi Sankyo, Janssen Pharma, and Konica Minolta REALM, Inc.; and payment or honoraria from MSD, Chugai, AstraZeneca, Merck Biopharma Co., Ltd., Novartis, Amgen, Daiichi Sankyo, and Thermo Fisher Scientific, all outside the submitted work. TK has received grants or contracts from AMED, Sysmex and Chugai; royalties or licenses from Thermo Fisher Scientific, Guardant Health Japan, Foundation Medicine and Konica Minolta REALM, Inc.; consulting fees from Eli Lilly; and honoraria for lectures from Eli Lilly, all outside the submitted work. Yuichiro Ohe has received grants or contracts from AstraZeneca, Chugai, Eli Lilly, Ono, Bristol Myers Squibb, Pfizer, MSD, Bayer, Nippon Kayaku, Kyowa Hakko Kirin, Eisai, Daiichi Sankyo, Boehringer Ingelheim, Taiho, Kyorin, Dainippon-Sumitomo, Novartis, Takeda, Kissei, and Janssen Pharma, and honoraria for speakers from AstraZeneca, Chugai, Eli Lilly, Ono, Bristol Myers Squibb, Kyorin, Celltrion, Boehringer Ingelheim, Bayer, Pfizer, MSD, Eisai, Daiichi Sankyo, Taiho, Nippon Kayaku, Kyowa Hakko Kirin, Amgen, and AnHeart Therapeutics Inc. all outside the submitted work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent for research use of biospecimens was obtained from patients diagnosed with NSCLC between 2000 and 2022, with the option to withdraw consent at any time. Only samples from patients who did not withdraw their consent were included in this study. For patients treated prior to 2000, a summary of the study was made publicly available on the official hospital website, and those who opted out were excluded. Patients who explicitly declined to provide consent for the use of their residual samples were also excluded. This study was approved by the Ethics Committee of the National Cancer Center Hospital (approval numbers: 2005-109, 2019-123) and conducted in accordance with the principles of the Declaration of Helsinki, as revised in Fortaleza, Brazil, in 2013.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable. Written informed consent or opt-out consent based on a publicly available study information document was obtained from all participants.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}